Galecto's listing in the US stock exchange has lead to some changes for the Danish biotech firm.
The people behind the Danish Capital fund Sunstone Life Science recently stepped out of its board and it seems Galecto has found their replacement. Because Galecto has announced that it has gained a new member of the board in Jayson Dallas.
Most recently, Jayson Dallas was the Presiden & CEO at the biotech Aimmune Therapeutics, which has garnered attention for its work towards finding a treatment for peanut allergy. The company was sold to Nestlé's health division earlier in the year, after which Jayson Dallas also left the firm.
I am delighted to welcome Jayson to the Galecto Board of Directors. His expertise in all aspects of the healthcare industry, from biotech to big pharma and drug development to commercialization, will be an important source of knowledge and guidance for Galecto as we continue through an exciting period of growth."
After Galecto became listed on the stock exchange, the firm has found a solid financial foundation – shortly before getting listed, the company fetched some money from private investors – and as such the firm expects to start all of three phase II trials in the next couple of months.
Would you like to receive the latest news from MedWatch directly in your e-mail inbox? Sign up for our free English newsletter below.
New Nordic fund prone for second investment – pours millions into antiviral spinout
Venture veterans raise EUR 76 million for new life science fund
Novo Seeds partner wants to raise millions for Nordic life science: "There is a dire need"
More from MedWatch
WS Audiology lives up to topline growth expectations – sees challenges ahead
The hearing giant reported 7% organic revenue growth for the financial year, though macroeconomic conditions have led the firm to be more conservative with next year’s estimates.
WS Audiology CEO expects market slowdown to continue in coming months
The hearing aid manufacturer is expecting growth in fiscal 2022/2023 to be under its recent annual result due to a market decline that looks to continue into the future, says CEO Eric Bernard.
Bavarian Nordic grants all employees an extra four days off
After a busy year at the Danish drugmaker, the firm has decided to give something back to its workers in the shape of four days extra vacation time.
Bank believes in cancer approval for Genmab
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
WSA CEO says Kirkland Signature absence at Costco has helped
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.
Quality Compliance Specialist 
Department Manager for Chemistry & Radiochemistry at Minerva Imaging 
Project Director of CMC & Device, Zealand Pharma A/S / 1801 
Project Lead, Regulatory Affairs 
Chief consultant for Dansk Erhvervs Health and life science 
Principal Systems Engineer 
New Product Introduction Manager Nordics 
Supply Chain Manager 
Strategic advisor and negotiator with in-depth knowledge of the pharmaceutical market 
Regulatory Affairs Manager 
Associate, CMC Project Management 
Head of Engineering